#89 Viscosupplementation (Hyaluronic Acid or Hylan): Cushioning the Blow (To Your Wallet)?
CLINICAL QUESTION
Do injections of viscosupplements (hylan or hyaluronic acid) improve symptoms of knee osteoarthritis?
BOTTOM LINE
Research on viscosupplementation (hylan or hyaluronic acid) for knee osteoarthritis has frequently been of poor quality and has exaggerated effectiveness. The best evidence indicates no meaningful benefit (if any at all) with potential adverse events (including cost).
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
At least 8 systematic reviews. Focus on the best and consider others.
Rutjes 2012:1 89 randomized controlled trials (RCTs) with 12,667 patients (mean age 63), median follow-up 16 years
- Reduction in pain (at 3 months), effect size -0.37 (-0.28 to -0.46)
- Just reached minimally important clinical benefit (-0.37 = 9 mm on 100 mm pain scale)
- But many issues,
- Higher quality studies (>100 patients, proper randomization, or blinded outcome assessor) found no clinically meaningful improvement in pain or function
- Publication bias: Negative trials less likely to be published. Five of 6 unpublished studies provided data and showed no effect.
- Adverse events increased
- Serious adverse events: Relative risk 1.41 (1.02-1.97)
- Dropouts due to adverse events: Relative risk 1.33 (1.01-1.74).
- Versus intra-articular placebo: Effect size -0.34 (-0.26 to -0.42)
- No difference versus intra-articular corticosteroid: Effect size -0.02 (+0.12 to -0.17)
- Large placebo effect (expectation bias) from intra-articular administration of medications,
- Intra-articular placebo versus oral placebo: Effect size -0.29 (-0.04 to -0.54).
- Similar results3,4
- No difference in patients reporting global improvement5
- Placebo injections similar to viscosupplementation6
- Clinically meaningful difference not discussed or rarely attained3-8
- Higher quality studies showed smaller benefit3,7
- Patients >65 years with more advanced radiographic osteoarthritis may be less likely to benefit.8
- While the conclusions of some systematic reviews are positive,5-8 these ignore clinically meaningful outcomes and/or include poor-quality, biased studies.
- Systematic review examining the timing of viscosupplementation effect9
- Peak effect at 8 weeks: effect size -0.34 (-0.02 to -0.67) for high-quality studies
- Still less than 0.37 minimally important clinical difference.1
- Systematic review comparing hylan to hyaluronic acid found no difference (except hylan may have more adverse events).10
- Viscosupplementation (1-3 injections) costs $285-500.
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
